Dr Lalchandani Labs Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1002986,
    "name": "Dr Lalchand. Lab",
    "stock_name": "Dr Lalchand. Lab",
    "full_name": "Dr Lalchandani Labs Ltd",
    "name_url": "stocks-analysis/dr-lalchand-lab",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "20.50",
    "chg": 1.28,
    "chgp": "6.66%",
    "dir": 1,
    "prev_price": "19.22",
    "mcapval": "8.88 Cr",
    "mcap": "Micro Cap",
    "scripcode": 541299,
    "symbol": "",
    "ind_name": "Healthcare Services",
    "ind_code": 94,
    "indexname": "",
    "isin": "INE871Z01013",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": 28000,
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/dr-lalchand-lab-1002986-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "How has been the historical performance of Dr Lalchand. Lab?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-dr-lalchand-lab-3703832",
        "imagepath": "",
        "date": "2025-11-15 00:15:07",
        "description": "Answer:\nThe historical performance of Dr Lalchand. Lab shows a declining trend in net sales and profitability over the past few years, with a significant drop in total operating income from 11.28 Cr in Mar'22 to 4.45 Cr in Mar'25. The operating profit margin has fluctuated, peaking at 28.9% in Mar'24 before falling to 23.37% in Mar'25. Profit before tax also saw a decline, moving from 1.25 Cr in Mar'22 to 0.40 Cr in Mar'25, while profit after tax decreased from 0.93 Cr in Mar'22 to 0.42 Cr in Mar'25. The company’s total assets decreased from 18.12 Cr in Mar'22 to 15.75 Cr in Mar'25, and total liabilities also saw a reduction from 18.12 Cr to 15.75 Cr in the same period. Cash flow from operating activities has been stagnant, with no inflow reported in the last two years, although there was a net cash inflow of 1.00 Cr in Mar'25.\n\nBreakdown:\nDr Lalchand. Lab's financial performance has shown a notable decline..."
      },
      {
        "title": "When is the next results date for Dr Lalchand. Lab?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-dr-lalchand-lab-3691192",
        "imagepath": "",
        "date": "2025-11-11 23:19:45",
        "description": "Dr Lalchand. Lab is scheduled to declare its results on 14 November 2025...."
      },
      {
        "title": "Why is Dr Lalchand. Lab falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-dr-lalchand-lab-fallingrising-3687285",
        "imagepath": "",
        "date": "2025-11-10 23:27:21",
        "description": "As of 10-Nov, Dr Lalchandani Labs Ltd is experiencing a decline in its stock price, currently at Rs 20.23, which reflects a decrease of Rs 1.06 or 4.98%. The stock has underperformed its sector by 3.4% today and opened with a loss of 4.98%. It has shown erratic trading patterns, not trading on 3 out of the last 20 days, and has touched an intraday low of Rs 20.23. Additionally, the delivery volume has decreased by 23.08% compared to the 5-day average, indicating falling investor participation. Over the past week, the stock has declined by 9.73%, while it has shown a year-to-date increase of 19.70%.\n\nIn the broader market context, the Sensex has only decreased by 0.53% over the past week, suggesting that the stock's decline is more pronounced than the overall market trend. While the stock has performed well year-to-date and over the past year, with increases of 19.70% and 12.39% respectively, its long-term p..."
      },
      {
        "title": "Why is Dr Lalchand. Lab falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-dr-lalchand-lab-fallingrising-3605211",
        "imagepath": "",
        "date": "2025-10-08 23:36:40",
        "description": "As of 08-Oct, Dr Lalchandani Labs Ltd is experiencing a decline in its stock price, currently at Rs 21.58, reflecting a decrease of Rs 1.13 or 4.98%. The stock has underperformed its sector by 5% today and opened with a significant loss of 4.89%. It has also touched an intraday low of Rs 21.58, indicating a challenging trading day. Over the past week, the stock has decreased by 4.98%, and its performance over the last month shows a decline of 16.97%. Despite these short-term challenges, the stock has shown a year-to-date increase of 27.69%, although it has underperformed the benchmark Sensex, which has risen by 4.65% during the same period. The stock's trading activity has been erratic, with no trades on 4 out of the last 20 days, but there has been a rise in investor participation, with delivery volume increasing by 36.36% compared to the 5-day average.\n\nBroader Market Context: In the context of the broade..."
      },
      {
        "title": "Why is Dr Lalchand. Lab falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-dr-lalchand-lab-fallingrising-3555201",
        "imagepath": "",
        "date": "2025-09-22 23:03:08",
        "description": "As of 22-Sep, Dr Lalchandani Labs Ltd's stock price is currently at 23.90, reflecting an increase of 0.89 or 3.87%. The stock has shown a trend reversal, gaining after 13 consecutive days of decline. Despite this positive movement today, the stock has underperformed in the short term, with a 1-week return of -8.01%. However, over the past month, it has increased by 4.18%, and year-to-date, it has risen significantly by 41.42%. The stock's performance today has outpaced its sector by 4.3%. Notably, there has been a substantial drop in investor participation, with delivery volume falling by 89.8% against the 5-day average, indicating a potential concern regarding liquidity and investor confidence.\n\nBroader market context shows that while Dr Lalchandani Labs Ltd has experienced a positive return over the past month and year-to-date, it has lagged behind the benchmark Sensex in the short term, which has gained ..."
      },
      {
        "title": "Is Dr Lalchand. Lab overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-dr-lalchand-lab-overvalued-or-undervalued-3550172",
        "imagepath": "",
        "date": "2025-09-22 08:07:03",
        "description": "As of 19 September 2025, the valuation grade for Dr Lalchand Lab has moved from expensive to attractive, indicating a significant shift in its market perception. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE ratio of 9.97, an EV to EBITDA of 10.33, and a Price to Book Value of 1.00, which are notably lower than many peers in the healthcare sector.\n\nIn comparison, Apollo Hospitals has a PE ratio of 71.29 and an EV to EBITDA of 36.65, while Max Healthcare is even higher at a PE of 93.83 and an EV to EBITDA of 58.13, highlighting the relative attractiveness of Dr Lalchand Lab. The company's recent stock performance has also shown resilience, with a year-to-date return of 36.15%, significantly outperforming the Sensex's 5.74% during the same period...."
      },
      {
        "title": "Is Dr Lalchand. Lab overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-dr-lalchand-lab-overvalued-or-undervalued-3549539",
        "imagepath": "",
        "date": "2025-09-21 08:06:18",
        "description": "As of 19 September 2025, the valuation grade for Dr Lalchand Lab has moved from expensive to attractive, indicating a significant shift in its perceived value. The company is currently assessed as undervalued. Key ratios supporting this conclusion include a PE ratio of 9.97, an EV to EBITDA ratio of 10.33, and a Price to Book Value of 1.00, all of which suggest a favorable valuation compared to its peers.\n\nIn comparison to its industry peers, Dr Lalchand Lab stands out with a much lower PE ratio than Apollo Hospitals, which has a PE of 71.29, and Max Healthcare, which is at 93.83. This stark contrast highlights Dr Lalchand Lab's relative attractiveness in the market. Additionally, while the company's stock has underperformed in the short term with a 1-week return of -11.43% compared to a 0.88% gain in the Sensex, its year-to-date return of 36.15% significantly outpaces the Sensex's 5.74%, reinforcing the no..."
      },
      {
        "title": "Is Dr Lalchand. Lab overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-dr-lalchand-lab-overvalued-or-undervalued-3541063",
        "imagepath": "",
        "date": "2025-09-20 08:06:51",
        "description": "As of 19 September 2025, the valuation grade for Dr Lalchand Lab has moved from expensive to attractive, indicating a significant shift in its perceived value. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE ratio of 9.97, an EV to EBITDA of 10.33, and a Price to Book Value of 1.00, all of which suggest a favorable valuation compared to its peers.\n\nIn comparison, Apollo Hospitals, which is also rated attractive, has a much higher PE ratio of 71.29 and an EV to EBITDA of 36.65, highlighting the relative undervaluation of Dr Lalchand Lab. Other peers like Max Healthcare and Fortis Health are categorized as very expensive, with PE ratios of 93.83 and 78.15, respectively. Despite a recent decline in stock price, Dr Lalchand Lab has shown a year-to-date return of 36.15%, outperforming the Sensex's 5.74%, reinforcing its attractive valuation proposition...."
      },
      {
        "title": "Why is Dr Lalchand. Lab falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-dr-lalchand-lab-fallingrising-3539760",
        "imagepath": "",
        "date": "2025-09-19 22:59:00",
        "description": "As of 19-Sep, Dr Lalchandani Labs Ltd is experiencing a decline in its stock price, currently at Rs 23.01, which represents a decrease of 1.21 or 5.0%. The stock has been underperforming, having fallen consecutively for the last two days and showing a significant drop of 11.43% over the past week. Today's trading saw the stock open with a loss of 5%, reaching an intraday low of Rs 23.01, and it has not traded above this price throughout the day. Additionally, there has been a notable decrease in investor participation, with delivery volume dropping by 63.64% compared to the five-day average, indicating reduced interest from traders. The stock's performance over various time frames shows a year-to-date increase of 36.15%, but it has underperformed the sector today by 4.81%.\n\nIn the broader market context, the Sensex has shown a positive return of 0.88% over the past week, contrasting with Dr Lalchandani Labs..."
      }
    ],
    "total": 53,
    "sid": "1002986",
    "stock_news_url": "https://www.marketsmojo.com/news/dr-lalchandani-labs-1002986"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Considering Of Raising Of Funds Through A Rights Issue And/Or Any Other Permissible Mode",
      "datetime": "02-Dec-2025",
      "details": "Dr Lalchandani Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/12/2025 inter alia to consider and approve raising of funds through a rights issue and/or any other permissible mode",
      "source": "BSE"
    },
    {
      "caption": "Unaudited Financials Results For The Half Year Ended September 30 2025",
      "datetime": "14-Nov-2025",
      "details": "Unaudited Financial results September 30 2025",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Unaudited Financial Results For The Half Year Ended September 2025",
      "datetime": "14-Nov-2025",
      "details": "Unaudited Financial Results for the half year ended September 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "09 Dec 2025"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

How has been the historical performance of Dr Lalchand. Lab?

2025-11-15 00:15:07

Answer: The historical performance of Dr Lalchand. Lab shows a declining trend in net sales and profitability over the past few years, with a significant drop in total operating income from 11.28 Cr in Mar'22 to 4.45 Cr in Mar'25. The operating profit margin has fluctuated, peaking at 28.9% in Mar'24 before falling to 23.37% in Mar'25. Profit before tax also saw a decline, moving from 1.25 Cr in Mar'22 to 0.40 Cr in Mar'25, while profit after tax decreased from 0.93 Cr in Mar'22 to 0.42 Cr in Mar'25. The company’s total assets decreased from 18.12 Cr in Mar'22 to 15.75 Cr in Mar'25, and total liabilities also saw a reduction from 18.12 Cr to 15.75 Cr in the same period. Cash flow from operating activities has been stagnant, with no inflow reported in the last two years, although there was a net cash inflow of 1.00 Cr in Mar'25. Breakdown: Dr Lalchand. Lab's financial performance has shown a notable decline...

When is the next results date for Dr Lalchand. Lab?

2025-11-11 23:19:45

Dr Lalchand. Lab is scheduled to declare its results on 14 November 2025....

Why is Dr Lalchand. Lab falling/rising?

2025-11-10 23:27:21

As of 10-Nov, Dr Lalchandani Labs Ltd is experiencing a decline in its stock price, currently at Rs 20.23, which reflects a decrease of Rs 1.06 or 4.98%. The stock has underperformed its sector by 3.4% today and opened with a loss of 4.98%. It has shown erratic trading patterns, not trading on 3 out of the last 20 days, and has touched an intraday low of Rs 20.23. Additionally, the delivery volume has decreased by 23.08% compared to the 5-day average, indicating falling investor participation. Over the past week, the stock has declined by 9.73%, while it has shown a year-to-date increase of 19.70%. In the broader market context, the Sensex has only decreased by 0.53% over the past week, suggesting that the stock's decline is more pronounced than the overall market trend. While the stock has performed well year-to-date and over the past year, with increases of 19.70% and 12.39% respectively, its long-term p...

Why is Dr Lalchand. Lab falling/rising?

2025-10-08 23:36:40

As of 08-Oct, Dr Lalchandani Labs Ltd is experiencing a decline in its stock price, currently at Rs 21.58, reflecting a decrease of Rs 1.13 or 4.98%. The stock has underperformed its sector by 5% today and opened with a significant loss of 4.89%. It has also touched an intraday low of Rs 21.58, indicating a challenging trading day. Over the past week, the stock has decreased by 4.98%, and its performance over the last month shows a decline of 16.97%. Despite these short-term challenges, the stock has shown a year-to-date increase of 27.69%, although it has underperformed the benchmark Sensex, which has risen by 4.65% during the same period. The stock's trading activity has been erratic, with no trades on 4 out of the last 20 days, but there has been a rise in investor participation, with delivery volume increasing by 36.36% compared to the 5-day average. Broader Market Context: In the context of the broade...

Why is Dr Lalchand. Lab falling/rising?

2025-09-22 23:03:08

As of 22-Sep, Dr Lalchandani Labs Ltd's stock price is currently at 23.90, reflecting an increase of 0.89 or 3.87%. The stock has shown a trend reversal, gaining after 13 consecutive days of decline. Despite this positive movement today, the stock has underperformed in the short term, with a 1-week return of -8.01%. However, over the past month, it has increased by 4.18%, and year-to-date, it has risen significantly by 41.42%. The stock's performance today has outpaced its sector by 4.3%. Notably, there has been a substantial drop in investor participation, with delivery volume falling by 89.8% against the 5-day average, indicating a potential concern regarding liquidity and investor confidence. Broader market context shows that while Dr Lalchandani Labs Ltd has experienced a positive return over the past month and year-to-date, it has lagged behind the benchmark Sensex in the short term, which has gained ...

Is Dr Lalchand. Lab overvalued or undervalued?

2025-09-22 08:07:03

As of 19 September 2025, the valuation grade for Dr Lalchand Lab has moved from expensive to attractive, indicating a significant shift in its market perception. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE ratio of 9.97, an EV to EBITDA of 10.33, and a Price to Book Value of 1.00, which are notably lower than many peers in the healthcare sector. In comparison, Apollo Hospitals has a PE ratio of 71.29 and an EV to EBITDA of 36.65, while Max Healthcare is even higher at a PE of 93.83 and an EV to EBITDA of 58.13, highlighting the relative attractiveness of Dr Lalchand Lab. The company's recent stock performance has also shown resilience, with a year-to-date return of 36.15%, significantly outperforming the Sensex's 5.74% during the same period....

Is Dr Lalchand. Lab overvalued or undervalued?

2025-09-21 08:06:18

As of 19 September 2025, the valuation grade for Dr Lalchand Lab has moved from expensive to attractive, indicating a significant shift in its perceived value. The company is currently assessed as undervalued. Key ratios supporting this conclusion include a PE ratio of 9.97, an EV to EBITDA ratio of 10.33, and a Price to Book Value of 1.00, all of which suggest a favorable valuation compared to its peers. In comparison to its industry peers, Dr Lalchand Lab stands out with a much lower PE ratio than Apollo Hospitals, which has a PE of 71.29, and Max Healthcare, which is at 93.83. This stark contrast highlights Dr Lalchand Lab's relative attractiveness in the market. Additionally, while the company's stock has underperformed in the short term with a 1-week return of -11.43% compared to a 0.88% gain in the Sensex, its year-to-date return of 36.15% significantly outpaces the Sensex's 5.74%, reinforcing the no...

Is Dr Lalchand. Lab overvalued or undervalued?

2025-09-20 08:06:51

As of 19 September 2025, the valuation grade for Dr Lalchand Lab has moved from expensive to attractive, indicating a significant shift in its perceived value. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE ratio of 9.97, an EV to EBITDA of 10.33, and a Price to Book Value of 1.00, all of which suggest a favorable valuation compared to its peers. In comparison, Apollo Hospitals, which is also rated attractive, has a much higher PE ratio of 71.29 and an EV to EBITDA of 36.65, highlighting the relative undervaluation of Dr Lalchand Lab. Other peers like Max Healthcare and Fortis Health are categorized as very expensive, with PE ratios of 93.83 and 78.15, respectively. Despite a recent decline in stock price, Dr Lalchand Lab has shown a year-to-date return of 36.15%, outperforming the Sensex's 5.74%, reinforcing its attractive valuation proposition....

Why is Dr Lalchand. Lab falling/rising?

2025-09-19 22:59:00

As of 19-Sep, Dr Lalchandani Labs Ltd is experiencing a decline in its stock price, currently at Rs 23.01, which represents a decrease of 1.21 or 5.0%. The stock has been underperforming, having fallen consecutively for the last two days and showing a significant drop of 11.43% over the past week. Today's trading saw the stock open with a loss of 5%, reaching an intraday low of Rs 23.01, and it has not traded above this price throughout the day. Additionally, there has been a notable decrease in investor participation, with delivery volume dropping by 63.64% compared to the five-day average, indicating reduced interest from traders. The stock's performance over various time frames shows a year-to-date increase of 36.15%, but it has underperformed the sector today by 4.81%. In the broader market context, the Sensex has shown a positive return of 0.88% over the past week, contrasting with Dr Lalchandani Labs...

View All News